Characterization of Adverse Drug Reaction Reports from Healthcare Staff in a Tertiary Healthcare Facility in Saudi Arabia
DOI:
https://doi.org/10.29070/g3f5qj12Keywords:
Adverse Drug Reactions (ADR), ADR reporting, PharmacovigilanceAbstract
According to the World Health Organization (WHO), adverse drug reactions (ADRs) are harmful and unintended effects that occur when medications are administered at doses commonly used for disease prevention, diagnosis, treatment, or for altering physiological functions. These reactions constitute a major global public health concern due to their impact on patient safety and healthcare systems worldwide [1].
ADRs are a major cause of morbidity and mortality, particularly in hospitalized patients [2]. Varying patterns of ADRs with non-uniform reporting have been observed in previous studies. The most reported ADRs in Saudi Arabia were in systemic anti-infective agents (22.27%) followed by antineoplastic and immunomodulating agents (21.49%). Specifically, serious ADRs were reported in vancomycin (2.7%), ceftriaxone (1.8 %), fingolimod (1.4 %), and paracetamol (1.4%) [9]. Males have been reported to have more ADRs with the reactions predominantly being cardiovascular (9.9%), followed by dermatological (9.5%) [10]. We aim to investigate ADRs reports at PSMMC we expect greater number of ADRs compared to previous local studies which will give us a clear look at drugs safety and efficacy at our population.
Downloads
References
1. International drug monitoring: the role of national centers. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972; 498:1-25. PMID: 4625548.
2. Mouton, J. P., Mehta, U., Parrish, A. G., Wilson, D. P., Stewart, A., Njuguna, C. W., Kramer, N., Maartens, G., Blockman, M., & Cohen, K. (2015). Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. British journal of clinical pharmacology, 80(4), 818–826. https://doi.org/10.1111/bcp.12567
3. Laroche, M., Tarbouriech, N., Jai, T., Valnet‐Rabier, M., & Nerich, V. (2024). Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16266
4. Priya nagar, Deepanshu kumar, Anjali kumari, & Piyush Mittal. (2023). pharmacoeconomics burden of adverse drug reaction; a scoping review article concise and informative article title. Journal of Population Therapeutics and Clinical Pharmacology, 30(17), 1508-1522. https://doi.org/10.53555/jptcp.v30i17.2783
5. Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract. 2017; 6:91-98. Published 2017 Mar 22. doi:10.2147/IPRP.S105881.
6. Pharmacovigilance. (2024, October 4). https://www.who.int/teams/regulation-prequalification/pharmacovigilance
7. Sienkiewicz, K., Burzyńska, M., Rydlewska-Liszkowska, I., Sienkiewicz, J., & Gaszyńska, E. (2021). The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process. International journal of environmental research and public health, 19(1), 413. https://doi.org/10.3390/ijerph19010413
8. Alharf, A., Alqahtani, N., Saeed, G., Alshahrani, A., Alshahrani, M., Aljasser, N., Alquwaizani, M., & Bawazir, S. (2018). Saudi Vigilance Program: Challenges and lessons learned. Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society, 26(3), 388–395. https://doi.org/10.1016/j.jsps.2018.01.002
9. Bin Yousef, N., Yenugadhati, N., Alqahtani, N., Alshahrani, A., Alshahrani, M., Al Jeraisy, M., & Badri, M. (2022). Patterns of adverse drug reactions (ADRs) in Saudi Arabia. Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society, 30(1), 8–13. https://doi.org/10.1016/j.jsps.2021.08.014
10. Alenzi, K. A., Alanazi, N. S., Almalki, M., Alomrani, H., & Alatawi, F. O. (2022). The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study. Saudi Pharmaceutical Journal, 30(6), 735–741. https://doi.org/10.1016/j.jsps.2022.03.018
11. Lobo MG, Pinheiro SM, Castro JG, Momenté VG, Pranchevicius MC. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol. 2013; 14:5. Published 2013 Jan 8. doi:10.1186/2050-6511-14-5.
12. Ahmed Bakri H, Jaly AA. Antibiotics-Related Adverse Drug Reaction in a Tertiary Hospital in Saudi Arabia: A Cohort, Retrospective Study. Cureus. 2023;15(5): e38431. Published 2023 May 2. doi:10.7759/cureus.38431.
13. Zucker, I., & Prendergast, B. J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of sex differences, 11(1), 32. https://doi.org/10.1186/s13293-020-00308-5
14. Hendriksen, L.C., van der Linden, P.D., Lagro-Janssen, A.L.M. et al. Sex differences associated with adverse drug reactions resulting in hospital admissions. Biol Sex Differ 12, 34 (2021). https://doi.org/10.1186/s13293-021-00377-0
15. Esba, L. C. A., Mardawi, G. A., AlJasser, M. I., Aljohani, B., & Alburak, A. A. (2020). Adverse drug reactions spontaneously reported at a tertiary care hospital and preventable measures implemented. Journal of Clinical Pharmacy and Therapeutics, 46(2), 460–469. https://doi.org/10.1111/jcpt.13306
16. Insani, W.N., Wei, L., Abdulah, R. et al. Exploring the association of adverse drug reactions with medication adherence and quality of life among hypertensive patients: a cross-sectional study. Int J Clin Pharm 47, 354–364 (2025). https://doi.org/10.1007/s11096-024-01832-9
17. Costa, C., Abeijon, P., Rodrigues, D.A. et al. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm 45, 1349–1358 (2023). https://doi.org/10.1007/s11096-023-01592-y
This work is licensed under a 